Effect of metyrapone on the fluoxetine-induced change in extracellular dopamine, serotonin and their metabolites in the rat frontal cortex

Pharmacological Reports

Volumn 62, Issue 6, 2010, Pages 1015-1022

  Rogóz, Zofia ^a   Gołembiowska, Krystyna ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

Fluoxetine; Metyrapone; Microdialysis; Monoamines; Rats

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; 5 HYDROXYINDOLEACETIC ACID; DOPAMINE; FLUOXETINE; HOMOVANILLIC ACID; METYRAPONE; SEROTONIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC TRANSMISSION; DRUG MECHANISM; DRUG POTENTIATION; ELECTROCHEMICAL DETECTION; FRONTAL CORTEX; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MICRODIALYSIS; NONHUMAN; RAT;

EID: 79551486708     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(10)70363-7     Document Type: Article

References (55)

1. Baez M, Volosin M: Corticosterone influences forced swim-induced immobility. Pharmacol Biochem Behav, 1994, 49, 729-736.
2. Bschor T, Canata B, Muller-Oerlinghausen B, Bauer M: Predictors of response to lithium augmentation in tricyclic antidepressant-resistant depression. J Affect Disord, 2001, 64, 261-265.
3. Bymaster FP, Zhang W, Carter PA, Shaw J, Chernet E, Phebus L, Wong DT, Perry KW: Fluoxetine, but not other selective serotonin uptake inhibitors, increases noradrenaline and dopamine extracellular levels in prefrontal cortex. Psychopharmacology (Berl), 2002, 160, 353-361. (Pubitemid 34253277)
4. Carboni E, Tanda GL, Frau R, Di Chiara G: Blockade of the noradrenaline carrier increases extracellular dopamine concentrations in the prefrontal cortex: evidence that dopamine is taken up in vivo by noradrenergic terminals. J Neurochem, 1990, 55, 1067-1070.
5. 1A receptor mRNA expression. Trends Neurosci, 1993, 13, 914-923.
6. Daniel WA, Syrek M, Haduch A: The contribution of cytochrome P-450 isoenzymes to the metabolism of phenothiazine neuroleptics. Eur Neuropsychopharmacol, 2002, 12, 371-377.
7. Dimitriou EC, Dimitriou CE: Buspirone augmentation of antidepressant therapy. J Clin Psychopharmacol, 1998, 18, 465-469.
8. 1A receptors. Neurochem Res, 1996, 21, 557-562.
9. Felton TM, Kang TB, Hjorth S, Auerbach SB: Effect of selective serotonin and serotonin/noradrenaline reuptake inhibitors on extracellular serotonin in rat diencephalons and frontal cortex. Naunyn Schmiedebergs Arch Pharmacol, 2003, 367, 297-305.
10. Healy DG, Harkin A, Cryan JF, Kelly JP, Leonard BE: Metyrapone displays antidepressant-like properties in preclinical paradigms. Psychopharmacology, 1999, 145, 203-208.
11. Heuser IJ, Schweiger U, Gotthardt U, Schmider J, Lammers CH, Dettling M, Yassouridis A, Holsboer F: Pituitary-adrenal-system regulation and psychopathology during amitriptyline treatment in elderly depressed patients and normal comparison subjects. Am J Psychiatry, 1996, 153, 93-99. (Pubitemid 26026163)
12. Holsboer F: The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology, 2000, 23, 477-501.
13. Holsboer F, Barden N: Antidepressants and hypothalamic-pituitary- adrenalcortical regulation. Endocrine Rev, 1996, 17, 187-205.
14. Holsboer F, Gerken A, Stalla GK, Muller O: ACTH, cortisol and corticosterone output after ovine corticotrophinreleasing factor challenge during depression and after recovery. Biol Psychiatry, 1985, 20, 276-286.
15. Huang M, Ichiwara J, Li Z, Dai J, Meltzer HY: Augmentation by citalopram of risperidone-induced monoamine release in rat prefrontal cortex. Psychopharmacology, 2006, 185, 274-281.
16. Iyer RN, Bradberry CW: Serotonin-mediated increase in prefrontal cortex dopamine release: pharmacological characterization. J Pharmacol Exp Ther, 1996, 277, 40-47.
17. Jahn H, Schick M, Kiefer F, Kellner M, Yassouridias A, Wiedemann K: Metyrapone as additive treatment in major depression: a double-blind and placebo-controlled trial. Arch Gen Psychiatry, 2004, 61, 1235-1244.
18. Jeffcoate WJ, Silverstone JT, Edwards CR, Besser GM: Psychiatric manifestations of Cushing's syndrome: response to lowering of plasma cortisol. Q J Med, 1979, 48, 465-472. (Pubitemid 10200362)
19. Jordan S, Kramer GL, Zukas PK, Moeller M, Petty F: In vivo biogenic amine efflux in medial prefrontal cortex with imipramine, fluoxetine, and fluvoxamine. Synapse, 1994, 18, 294-297.
20. Kelly JP, Leonard BE: The effect of tianeptine and sertraline in three animal models of depression. Neuropharmacology, 1994, 33, 1011-1016.
21. Kishimoto W, Hiroi T, Shiraishi M, Osada M, Imaoka S, Kominami S, Igarashi T, Funae Y: Cytochrome P450 2D catalyze steroid 21-hydroxylation in the brain. Endocrinology, 2004, 145, 699-705.
22. Koch S, Perry KW, Bymaster FP: Brain region and dose effects of an olanzapine/fluoxetine combination on extracellular monoamine concentrations in the rat. Neuropharmacology, 2004, 46, 232-242.
23. Koch S, Perry KW, Nelson DL, Conway RG, Threlkeld PG, Bymaster FP: R-fluoxetine increases extracellular DA, NA, as well as 5-HT in rat prefrontal cortex and hypothalamus: an in vivo microdialysis and receptor binding study. Neuropsychopharmacology, 2002, 27, 949-959.
24. Korstein SG, Schneider RK: Clinical festures of treatment-resistant depression. J Clin Psychiatry, 2001, 62, Suppl 16, 18-25.
25. Linkowski P, Mendlewicz J, LeClerc R, Brasseur M, Hubain P, Goldstein J, Copinschi G, Van Cauter E: The 24-hour profile of ACTH and cortisol in major depressive illness. J Clin Endocrinol Metab, 1985, 61, 429-438. (Pubitemid 15243950)
26. Maes M, Vandoolaeghe E, Desnyder R: Efficacy of treatment with trazodone in combination with pindolol or fluoxetine in major depression. J Affect Disord, 1996, 41, 201-210. (Pubitemid 26422950)
27. Matsumoto M, Togashi H, Mori K, Ueno K, Miyamoto A, Yoshioka M: Characterization of endogenous serotonin-mediated regulation of dopamine release in the rat prefrontal cortex. Eur J Pharmacol, 1999, 383, 39-48. (Pubitemid 29509820)
28. Murphy BEP: Antiglucocorticoid therapies in major depression: a review. Psychoendocrinology, 1997, 22, Suppl 1, S125-S132.
29. Nemeroff CB, Widerlöv E, Bisette G, Walléus H, Karlsson I, Eklund K, Kilts CD et al.: Elevated concentrations of CRF corticotropin releasing factor-like immunoreactivity in depressed patients. Science, 1984, 226, 1342-1344.
30. O'Brien D, Skelton KH, Owens MJ, Nemeroff CB: Are CRF receptor antagonists potential antidepressants? Hum Psychopharmacol, 2001, 16, 81-87.
31. O'Dwyer A-M, Lightman SL, Marks MKN, Checkley SA: Treatment of major depression with metyrapone and hydrocortisone. J Affect Disord, 1995, 33, 123-128.
32. Otton SV, Wu D, Joffe RT, Cheung SW, Sellers EM: Inhibition of fluoxetine of cytochrome P450 2D6 activity. Clin Pharmacol Ther, 1993, 53, 401-409. (Pubitemid 23119426)
33. Pariante CM, Miller AH: Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment. Biol Psychiatry, 2001, 49, 391-404. (Pubitemid 32234301)
34. Perry KW, Fuller RW: Effect of fluoxetine on serotonin and dopamine concentration in microdialysis fluid from rat striatum. Life Sci, 1992, 50, 1683-1690.
35. Perry KW, Fuller RW: Fluoxetine increases noradrenaline release in rat hypothalamus as measured by tissue levels of MHPG-SO4 and microdialysis in conscious rat. J Neural Transm, 1997, 104, 953-966.
36. Pozzi L, Invernizzi R, Cervo L, Vallebuona F, Samanin R: Evidence that extracellular concentrations of dopamine are regulated by noradrenergic neurons in the frontal cortex of rats. J Neurochem, 1994, 63, 195-200.
37. Pozzi L, Invernizzi R, Garavagia C, Samanin R: Fluoxetine increases extracellular dopamine in the prefrontal cortex by a mechanism not dependent on serotonin: a comparison with citalopram. J Neurochem, 1999, 73, 1051-1057.
38. Price LH, Malison RT, McDougle CJ, Pelton GH: Antiglucocorticoids as treatments for depression. Rationale for use and therapeutic potential. CNS Drugs, 1996, 5, 311-320.
39. Raven PW, O'Dwyer A-M, Taylor NF, Checkley SA: The relationship between the effect of metyrapone treatment on depressed mood and urinary steroid profiles. Psychoneuroendocrinology, 1996, 21, 277-286.
40. Rogóż Z: Potentiation of the antidepressant-like effect of desipramine or reboxetine by metyrapone in the forced swimming test in rats. Pharmacol Rep, 2009, 61, 1173-1178.
41. Rogóż Z, Budziszewska B, Kubera M, Basta-Kaim A, Jaworska-Feil L, Skuza G, Lasoñ W: Effects of combined treatment with imipramine and metyrapone on the immobility time, the activity of hypothalamo-pituitary-adrenocortical axis and immunological parameters in the forced swimming test in the rat. J Physiol Pharmacol, 2005, 56, 49-61.
42. Rogóż Z, Skuza G, Leoekiewicz M, Budziszewska B: Effects of co-administration of fluoxetine or tianeptine with metyrapone on immobility time and plasma corticosterone concentration in rats subjected to the forced swim test. Pharmacol Rep, 2008, 60, 880-888.
43. Rogóż Z, Skuza G, Wójcikowski J, Daniel WA: Effect of combined treatment with imipramine and metyrapone in the forced swimming test in rats. Behavioral and pharmacokinetic studies. Pol J Pharmacol, 2003, 55, 993-999.
44. Rogóż Z, Skuza G, Wójcikowski J, Daniel WA, Wróbel A, Dudek D, Ziêba A: Effect of metyrapone supplementation on imipramine therapy in patients with treatmentresistant unipolar depression. Pol J Pharmacol, 2004, 56, 849-855.
45. Rupprecht R, Ströhle A, Hermann B, di Michele F, Spalletta G, Pasini F, Holsboer F, Romeo E: Neuroactive steroid concentrations following metyrapone administration in depressed patients and healthy volunteers. Biol Psychiatry, 1998, 44, 912-914. (Pubitemid 28520230)
46. Sanchez C, Hyttel J: Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. Cell Med Neurobiol, 1999, 19, 467-489.
47. th edn. Ed. Hardiman JG, Limbard LE, McGraw Hill, New York, 1996, 1459-1485.
48. Shelton RC: Treatment options for refractory depression. J Clin Psychiatry, 1999, 60, Suppl 4, 57-61.
49. Shelton RC, Papakostas GI: Augmentation of antidepressants with atypical antipsychotics for treatment-resistant major depressive disorder. Acta Psychiatr Scand, 2008, 117, 253-259.
50. Sprouse J, Clarke T, Reynolds L, Heym J, Rollema H: Comparison of the effects of sertraline and its metabolite desmethylsertraline on blockade of central 5-HT reuptake in vivo. Neuropsychopharmacology, 1996, 14, 225-231.
51. Tanda G, Carboni E, Fran R, Di Chiara G: Increase of extracellular dopamine in the prefrontal cortex: a trait of drugs with antidepressant potential? Psychopharmacology (Berl), 1994, 115, 285-288.
52. Turpeinen M, Nieminen R, Juntunen T, Taavitsainen P, Raunio H, Pelkonnen O: Selective inhibition of CYP2B6-catalyzed bupropion hydroxylase in human liver microsomes in vitro. Drug Metab Dispos, 2004, 32, 626-631.
53. Wright MC, Paine AJ, Skett P, Auld R: Induction of rat hepatic glucocorticoid inducible cytochrome P450 by metyrapone. J Steroid Biochem Mol Biol, 1994, 48, 271-276.
54. Yoshino T, Nisijma K, Shioda K, Yui K, Katoh S: Perospirone, a novel atypical antipsychotic drugs, potentiates fluoxetine-induced increases in dopamine levels via multireceptor actions in the rat medial prefrontal cortex. Neurosci Lett, 2004, 364, 16-21.
55. Zhang W, Perry KW, Wong DT, Potts BD, Bao JQ, Tollefson GD, Bymaster FP: Synergistic effect of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex. Neuropsychopharmacology, 2000, 23, 250-262.